|Tested species reactivity||Dog, Human, Rat|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Partially purified, full length recombinant human MAGE-1 protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunofluorescence (IF)||Assay Dependent|
|Immunohistochemistry (Paraffin) (IHC (P))||1:12.5-1:25|
|Western Blot (WB)||0.5-1.0 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-11338 targets MAGE-1 in IF, IHC (P), and WB applications and shows reactivity with Canine, Human, and Rat samples.
The MA5-11338 immunogen is partially purified, full length recombinant human MAGE-1 protein.
Human malignant neoplasms carry rejection antigens that are recognized by the patients' autologous, tumor directed and specific, cytolytic, CD8+ T lymphocyte clones (CTL). An important group of antigens is coded by the MAGE family of genes. It was identified that melanomas and primary glial brain tumors express common melanoma associated antigens (MAAs). Because MAGE-1 is expressed on a significant proportion of human neoplasms of various histological types (melanoma, brain tumors of glial origin, neuroblastoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, renal cell carcinomas) and not on normal tissues, the encoded antigen may serve as a marker of early detection and target for cancer immunotherapy
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
NFATc2 is an intrinsic regulator of melanoma dedifferentiation.
MA5-11338 was used in flow cytometry to identify NFATc2 as a regulator of human melanoma dedifferentiation
|Perotti V,Baldassari P,Molla A,Vegetti C,Bersani I,Maurichi A,Santinami M,Anichini A,Mortarini R||Oncogene (35:2862)||2016|
Establishment of stable cell lines for personalized melanoma cell vaccine.
MA5-11338 was used in immunocytochemistry to establish stable melanoma cell lines for personalized vaccine therapy
|Selvan SR,Carbonell DJ,Fowler AW,Beatty AR,Ravindranath MH,Dillman RO||Melanoma research (20:280)||2010|
Nestin is expressed in HMB-45 negative melanoma cells in dermal parts of nodular melanoma.
MA5-11338 was used in immunohistochemistry to study nestin expression in dermal parts of nodular melanoma
|Kanoh M,Amoh Y,Tanabe K,Maejima H,Takasu H,Katsuoka K||The Journal of dermatology (37:505)||2010|
Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy.
MA5-11338 was used in immunohistochemistry to study the therapeutic target potential of GAGE protein in cancers
|Gjerstorff MF,Johansen LE,Nielsen O,Kock K,Ditzel HJ||British journal of cancer (94:1864)||2006|
Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.
MA5-11338 was used in immunohistochemistry to investigate the expression of protein markers associated with melanoma and melanocytic differentiation in HMB45-negative melanomas
|Xu X,Chu AY,Pasha TL,Elder DE,Zhang PJ||The American journal of surgical pathology (26:82)||2002|
|Not Applicable||Not Cited||
Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR.
MA5-11338 was used in immunohistochemistry - paraffin section to identify and evaluate cancer-germline genes for therapeutic vaccine targets in various pediatric solid tumors
|Jacobs JF,Brasseur F,Hulsbergen-van de Kaa CA,van de Rakt MW,Figdor CG,Adema GJ,Hoogerbrugge PM,Coulie PG,de Vries IJ||International journal of cancer (120:67)||2007|